36336 Federal Register / Vol. 87, No. 116 / Thursday, June 16, 2022 / Notices 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of federally 

funded research and development. 

Foreign patent applications are filed on 

selected inventions to extend market 

coverage for companies and may also be 

available for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Yogikala Prabhu, Ph.D., 301–761–7789; 

prabhuyo@niaid.nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Methods for Using Modulators of 

Extracellular Adenosine or an 

Adenosine Receptor To Enhance 

Immune Response and Inflammation 

Description of Technology 

Local inflammation processes are 

crucially important in the host defense 

against pathogens and for successful 

immunization because proinflammatory 

cytokines are necessary for initiation 

and propagation of an immune 

response. However, normal 

inflammatory responses are eventually 

terminated by physiological termination 

mechanisms, thereby limiting the 

strength and duration of immune 

responses, especially to weak antigens. 

The inventors have shown that 

adenosine A2a and A3a receptors play 

a critical role in down-regulation of 

inflammation in vivo. They act as the 

physiological termination mechanism 

that can limit the immune response. 

Thus, a method was developed for 

inhibiting signaling through the 

adenosine receptor to prolong and 

intensify the immune response. The 

method involves administering either an 

adenosine-degrading drug or an 

adenosine receptor agonist. These 

compounds can be also used as vaccine 

adjuvants and treatments for 

accomplishing targeted tissue damage 

such as for tumor destruction. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Anti-tumor therapy 

• Vaccine adjuvants for tumors 

• Immunotherapy 

Competitive Advantages 

• Use of adenosine receptor agonist or 

adenosine-degrading drug to inhibit 

signaling through the adenosine 

receptor to prolong and intensify the 

immune response. 

• Use of adenosine receptor agonists 

or adenosine-degrading drugs as vaccine 

adjuvants for tumor destruction. 

Development Stage 

• Pre-clinical 

Inventors: Michail V. Sitkovsky, M.D. 

(previously at NIAID), Akio Ohta 

(previously at NIAID). 

Publications: Ohta A. et al., ‘‘Role of 

G-protein-coupled adenosine receptors 

in downregulation of inflammation and 

protection from tissue damage,’’ Nature 

2001 Dec 20–27; 414 (6866):916–20. 

Intellectual Property: HHS Reference 

No. E–051–2002–0. 

• U.S. Divisional Application No. 16/ 

391,423- filed April 23, 2019, entitled 

‘‘Methods for Using Modulators of 

Extracellular Adenosine or an 

Adenosine Receptor to Enhance 

Immune Response and Inflammation’’ 

[HHS Reference No. E–051–2002/0–US– 

19]. 

All issued and active U.S. patents 

(claiming priority to U.S. Provisional 

Application Nos 60/340,772 filed 

December 12, 2011, and 60/342,585 

filed December 19, 2001) related to the 

above-referenced technology: 

• U.S. Patent 8,080,554, issued 

December 20, 2011 (application 10/ 

498,416 filed on 06/10/2004) 

• U.S. Patent 8,716,301, issued May 06, 

2014 (application 13/310,264 filed on 

12/02/2001) 

• U.S. Patent 9,415,105, issued August 

16, 2016 (application 14/067,005 filed 

on 10/30/2013) 

• U.S. Patent 10,314,908, issued June 

11, 2019 (application 15/237,316 filed 

on 08/15/2016) 

Licensing Contact: To license this 

technology, please contact Yogikala 

Prabhu, Ph.D., 301–761–7789; 

prabhuyo@niaid.nih.gov, and reference 

E–051–2002–0. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Yogikala Prabhu, Ph.D., 301– 

761–7789; prabhuyo@niaid.nih.gov. 

Dated: June 10, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–12959 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Maximizing Opportunities for 

Scientific and Academic Independent 

Careers (MOSAIC) Postdoctoral Career 

Transition Award to Promote Diversity (K99/ 

R00). 

Date: July 26, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of General 

Medical Sciences, Natcher Building, 45 

Center Drive, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Lisa A. Dunbar, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, Room 3AN12, Bethesda, MD 

20892, 301–594–2849, dunbarl@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives; 93.859, 

Biomedical Research and Research Training, 

National Institutes of Health, HHS) 

Dated: June 10, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12927 Filed 6–15–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES